ICD10 Poviders Claim Codes 2016

Transcription

1 ICD10 Poviders Claim 2016 ACOG Recommendations for Women s Health Screenings and Care Alcohol Abuse Screening Asymptomatic Bacteriuria Screening Autism Screening BRCA1 and BRCA2 Testing Breast Cancer, Screening Breastfeeding Support Supplies and Counseling Cervical Cancer Screening Chlamydia Screening Colorectal Cancer Screenings Condoms (Male-Female) Spermicide (Foam-Sponge) Contraceptive Injections Dental Care Preventive Diabetes Screening Diaphragm Gonorrhea Screening Hearing Screenings Hepatitis B Screening HIV Screening HPV Screening with Normal Cytology Results Hypertension Screening Hypothyroidism, Congenital Screening Immunizations (CDC) Adult Immunizations (CDC) Aged 0-6 years Immunizations (CDC) Aged 7-18 years Implantable Rod Intrauterine Device Iron Deficiency Anemia Screening Lead Testing (HCR) Lipid Disorders Screening

2 Newborn Hematocrit or Hemoglobin Newborn Metabolic Screening Newborn TB (Tuberculin) Tests Nutritional Counseling Obesity Screening Oral Contraceptives Osteoporosis Screening Phenylketonuria (PKU) Screening Prenatal Tests - Routine Rh (D) Incompatibility Screening Screening and Counseling for Interpersonal and Domestic Violence Sexually Transmitted Counseling Sickle Cell Testing Syphilis Infection Screening The Morning After Pill Tobacco Counseling Transabdominal Surgical Sterilization - Surgical Implant Transcervical Surgical Sterilization - Surgical Implant Vaginal Contraceptive Ring Vasectomy Vision Screening

3 ACOG Recommendations for Women s Health Screenings and Care Provider Claims CPT Screening mammography, bilateral (2-view film study of each breast) Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine) Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; appendicular skeleton (peripheral) (eg, radius, wrist, heel) Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided three cards or single triple card for consecutive collection) Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision Cytopathology, slides, cervical or vaginal; manual screening under physician supervision Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision Cytopathology, slides, cervical or vaginal; with manual 12/27/2010 sbm Completed 01/03/2011 sbm Osteoporosis screening codes added 10/03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 1

4 ACOG Recommendations for Women s Health Screenings and Care screening and rescreening under physician supervision Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision Cytopathology, slides, cervical or vaginal, definitive hormonal evaluation (eg, maturation index, karyopyknotic index, estrogenic index) (List separately in addition to code[s] for other technical and interpretation services) Cytopathology, smears, any other source; screening and interpretation Cytopathology, smears, any other source; preparation, screening and interpretation Cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and rescreening under physician supervision Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening under physician supervision Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening using cell selection and review under physician supervision Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care physician or other qualified health care professional; first vaccine/ toxoid component Code effective 01/01/ /27/2010 sbm Completed 01/03/2011 sbm Osteoporosis screening codes added 10/03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 2

5 ACOG Recommendations for Women s Health Screenings and Care Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care physician or other qualified health care professional; each additional vaccine/toxoid component (List separately in addition to code for primary procedure) Code effective 01/01/ Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine (single or combination vaccine/toxoid) Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) Human Papilloma virus (HPV) vaccine, types 6, 11, 16, 19 (quadrivalent), 3 dose schedule, for intramuscular use Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to 7 years or older, for intramuscular use Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetravalent), for intramuscular use New and Established patient evaluation and management New and Established preventive medicine evaluations Preventive Medicine, Individual Counseling HCPC G0101 G0202 G0328 G0433 Cervical or vaginal cancer screening; pelvic and clinical breast examination Screening mammography, producing direct digital image, bilateral, all views Colorectal cancer screening; fecal-occult blood test, immunoassay, 1-3 simultaneous determinations Infectious agent antigen detection by enzyme-linked immunosorbent assay (ELISA) technique, antibody, HIV-1 or HIV-2, screening 12/27/2010 sbm Completed 01/03/2011 sbm Osteoporosis screening codes added 10/03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 3

6 ACOG Recommendations for Women s Health Screenings and Care G0435 Infectious agent antibody detection by rapid antibody test, HIV-1 and/or HIV-2, screening P3000 Screening Papanicolaou smear, cervical or vaginal, up to 3 smears, by technician under physician supervision P3001 Screening Papanicolaou smear, cervical or vaginal, up to 3 smears, requiring interpretation by physician Q0091 S0613 ICD-10-CM Diagnosis ZØ1.411 ZØ1.419 Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory Annual gynecological examination; clinical breast examination without pelvic evaluation Encounter for gynecological examination (general) routine) with abnormal findings Encounter for gynecological examination (general) routine) without abnormal findings Z11.51 Encounter for screening for Human Papillomavirus (HPV) Z12.31 Encounter for screening mammogram for malignant neoplasm of breast Z12.39 Encounter for other screening for malignant neoplasm of breast Z12.4 Encounter for screening for malignant neoplasm of cervix Z12.12 Encounter for screening for malignant neoplasm of rectum Z12.72 Encounter for screening for malignant neoplasm of vagina Z12.11 Encounter for screening for malignant neoplasm of colon Z13.82Ø Encounter for screening for osteoporosis 12/27/2010 sbm Completed 01/03/2011 sbm Osteoporosis screening codes added 10/03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 4

7 ACOG Recommendations for Women s Health Screenings and Care ACOG Releases Revised Recommendations for Women's Health Screenings and Care Washington, DC -- Recent recommendations for HIV screening, human papillomavirus (HPV) vaccination, and preconception care are among those highlighted in the revised primary and preventive care periodic assessments recommended for women by The American College of Obstetricians and Gynecologists (ACOG). The updated recommendations, published in the December issue of Obstetrics & Gynecology, provide ob-gyns with a comprehensive schedule of age-appropriate screening exams, laboratory tests, immunizations, and counseling for nonpregnant adolescents and adult women. The document incorporates recent guidance from individual ACOG committees on specific issues in women's health. HIV Testing Routine HIV testing should be offered to women ages 19 to 64 regardless of personal risk factors, following the new Centers for Disease Control and Prevention (CDC) guidelines. Obgyns should be aware of and follow their states' HIV testing requirements. In addition, ACOG recommends HIV testing for adolescents who are or ever have been sexually active. ACOG previously recommended HIV testing only for women considered high risk or for those in areas with high HIV prevalence. Preconception Care Ob-gyns should encourage women of childbearing age to develop a reproductive health plan to help conscientiously assess the desire for a child or children or desire not to have children. The plan also should address the optimal number, timing, and spacing of children; determine the steps needed to prevent or plan for and optimize a pregnancy; and evaluate current health status and other issues relevant to the health of a pregnancy. Colorectal Cancer Screening Women age 50 and older should be screened for colorectal cancer using one of five recommended screening strategies. If fecal occult blood testing (FOBT) is used, patients should collect two or three samples at home and return them for laboratory analysis. Single samples obtained by digital rectal examination in the ob-gyn's office are not adequate for colorectal cancer screening. HPV Vaccine An HPV vaccine was made available for the first time in ACOG recommends that HPV vaccination be offered to all girls and women 9 to 26 who have not previously been vaccinated. The vaccine protects against four HPV strains that cause most cervical cancers and genital warts and is most effective when administered before the onset of sexual activity. Tdap Vaccine Pertussis has been added to the tetanus and diphtheria booster recommendation in accordance with CDC recommendations. Adolescents should receive the Tetanus, Diptheria, 12/27/2010 sbm Completed 01/03/2011 sbm Osteoporosis screening codes added 10/03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 5

8 ACOG Recommendations for Women s Health Screenings and Care accordance with CDC recommendations. Adolescents should receive the Tetanus, Diptheria, Pertussis (Tdap) booster once between ages 11 and 16, then every 10 years thereafter up to age 64. Meningococcal Vaccine ACOG now recommends that adolescents not previously immunized receive meningococcal conjugate vaccination before entry into high school. Older women at high risk also should receive the vaccine. Retrieved December 23, 2010 from the ACOG website at Best regards, Robert A. Ziff, MD, MBA, FACS, CPE Medical Director, Ohio Medicare Routine office visits provide opportunities for preventive screening, evaluation, and counseling. The American College of Obstetricians and Gynecologists (ACOG) regularly updates its recommendations for screening. Now, new guidelines address periodic assessment in four patient age groups: 13 to 18, 19 to 39, 40 to 64, and 65. Highlights of the guidelines are: Screening for sexually transmitted infections (STIs) in young women: Although ACOG recommends that cervical cytology be deferred until age 21, STI screening is encouraged for all sexually active patients younger than 25. ACOG recommends pelvic examination in women younger than 21 only when indicated. If pelvic examinations are not performed in sexually active patients younger than 21, urine-based screening for chlamydia and gonorrhea is recommended. Mammography: ACOG recommends that women be screened every 1 to 2 years beginning at age 40, with annual screening beginning at age 50. Bone-mineral density (BMD) assessment: For women without risk factors, screening with dual-energy x-ray absorptiometry should be initiated at age 65. In the absence of new risk factors, assessment should be repeated no more often than biennially. 12/27/2010 sbm Completed 01/03/2011 sbm Osteoporosis screening codes added 10/03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 6

9 ACOG Recommendations for Women s Health Screenings and Care Comment: In adolescents, I consider speculum examination to be indicated only if the patient complains of pain, abnormal bleeding, discharge, or odor. In the absence of such indications, use of urine-based STI screening will make office visits substantially more patient-friendly for our youngest sexually active patients. ACOG's guidance about screening mammography contrasts with that of the U.S. Preventive Services Task Force, which recommends biennial screening beginning at age 50 (JW Womens Health Nov ). I have observed that many women in their 50s who do not have specific risk factors for osteoporosis (JW Womens Health Feb ) nevertheless undergo BMD assessment, sometimes resulting in inappropriate long-term use of bisphosphonates. Deferring dualenergy x-ray absorptiometry in low-risk women until age 65 allows us to focus screening resources on women who are most likely to benefit from prescription antifracture therapy. This guideline watch includes only a few of the many screening and preventive strategies recommended by ACOG. I encourage readers to consult the guidelines directly for further information. Andrew M. Kaunitz, MD Published in Journal Watch Women's Health April 21, 2011 Citation(s): American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee opinion no. 483: Primary and preventive care: Periodic assessments. Obstet Gynecol 2011 Apr; 117:1008. ( Medline abstract (Free) 12/27/2010 sbm Completed 01/03/2011 sbm Osteoporosis screening codes added 10/03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 7

10 Alcohol Abuse Screening Provider Claims CPT Alcohol and/or substance (other than tobacco) abuse structured screening (eg, AUDIT, DAST), and brief intervention (SBI) services; 15 to 30 minutes Alcohol and/or substance (other than tobacco) abuse structured screening (eg, AUDIT, DAST), and brief intervention (SBI) services; greater than 30 minutes HCPC G0396 G0397 G0442 H0003 H0049 ICD-10-CM Alcohol and/or substance (other than tobacco) abuse structured screening (eg, AUDIT, DAST), and intervention (SBI) services; 15 to 30 minutes Alcohol and/or substance (other than tobacco) abuse structured screening (eg, AUDIT, DAST), and intervention (SBI) services; greater than 30 minutes Annual alcohol misuse screening, 15 minutes Alcohol and/or drug screening; laboratory analysis of specimens for presence of alcohol and/or drugs Alcohol and/or drug screening Z13.89 Encounter for screening for other disorder 05/12/2010 sbm Removed H0047 per Dr. Stemple, the remainder approved. 05/18/2010 sbm CERT approved, no changes 07/27/2010 sbm Approved by CERT members for Peds 12/09/2010 sbm 2010/2011 review completed, no changes 02/06/2012 sbm Addition of G0442 8

11 Asymptomatic Bacteriuria Screening Provider Claims CPT Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy Urinalysis; qualitative or semiquantitative, except immunoassays Urinalysis; bacteriuria screen, except by culture or dipstick Urinalysis; microscopic only ICD-10-CM Diagnosis Z34.ØØ-Z34.Ø Z34.8Ø-Z34.83 Z34.9Ø-Z34.93 OØ9.ØØ- OØ9.Ø3 OØ.Ø-OØ9.13 OØ OØ9.219 Encounter for supervision of normal first pregnancy Encounter for supervision of other normal pregnancy Encounter for supervision of normal pregnancy, unspecified Supervision of pregnancy with history of infertility Supervision of pregnancy with history of ectopic or molar pregnancy Supervision of pregnancy with history of pre-term labor 05/12/2010 sbm - Per Dr. Stemple, coding is correct but add prenatal codes 05/18/2010 sbm CERT approved, add 81000, 81001, 81002, 81003, 81005, 81007, 81015, deletion of 87077, 87086, 87088, 87184, , V28.0-V28.9, V /09/2010 sbm 2010/2011 review completed, no changes 02/06/2012 sbm 2012 review completed, no changes 9

12 Asymptomatic Bacteriuria Screening OØ OØ9.299 OØ9.3Ø- OØ9.33 OØ9.4Ø- OØ9.43 OØ OØ9.529 OØ OØ9.629 OØ9.7Ø- OØ9.73 OØ OØ9.93 Supervision of pregnancy with other poor reproductive or obstetric history Supervision of pregnancy with insufficient antenatal care Supervision of pregnancy with grand multiparity Supervision of elderly primigravida and multigravida Supervision of young primigravida and multigravida Supervision of high risk pregnancy due to social problems Supervision of other high risk pregnancies 05/12/2010 sbm - Per Dr. Stemple, coding is correct but add prenatal codes 05/18/2010 sbm CERT approved, add 81000, 81001, 81002, 81003, 81005, 81007, 81015, deletion of 87077, 87086, 87088, 87184, , V28.0-V28.9, V /09/2010 sbm 2010/2011 review completed, no changes 02/06/2012 sbm 2012 review completed, no changes 10

13 Autism Testing/Screening Provider Claims CPT Developmental testing; limited (eg, Developmental Screening Test II, Early Language Milestone Screen), with interpretation and report Developmental testing; extended (includes assessment of motor, language, social, adaptive and/or cognitive functioning by standardized developmental instruments) with interpretation and report Neurobehavioral status exam (clinical assessment of thinking, reasoning, and judgment, eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities), per hour of the psychologist s or physician s time, both face-to-face time with the patient and time interpreting test results and preparing the report 07/23/2010 sbm Completed 07/27/2010 sbm Approved by CERT members for Peds 12/09/2010 sbm 2010/2011 review completed, no changes 02/06/2012 sbm 2012 review completed 11

14 BRCA1 and BRCA2 Testing Provider Claims CPT BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon8-9 del 7.1kb) BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb) BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant Code effective 01/01/2012 Code effective 01/01/2012 Code effective 01/01/2012 Code effective 01/01/2012 Code effective 01/01/2012 Code effective 01/01/2012 Code effective 01/01/ Molecular diagnostics; molecular isolation or extraction, each nucleic acid type (ie, DNA or RNA) Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA) Molecular diagnostics; enzymatic digestion, each enzyme treatment Molecular diagnostics; dot/slot blot production, each nucleic acid preparation Molecular diagnostics; separation by gel electrophoresis (eg, agarose, polyacrylamide), each nucleic acid preparation Molecular diagnostics; nucleic acid probe, each Molecular diagnostics; nucleic acid transfer (eg, Southern, Northern), each nucleic acid preparation 05/12/2010 sbm preliminary approved by Dr. Stemple 05/26/2010 sbm List approved by Kira Prewitt-Eddy, MPA 12/09/2010 sbm 2010/2011 review completed, no changes 02/06/2012 sbm Addition of , 2012 CPT updates 02/07/2012 sbm Code list approved by Tammy Mullins, R.N. and Kira Prewitt-Eddy 12

15 BRCA1 and BRCA2 Testing Molecular diagnostics; amplification, target, each nucleic acid sequence Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences Molecular diagnostics; amplification, target, multiplex, each additional nucleic acid sequence beyond 2 (List separately in addition to code for primary procedure) Molecular diagnostics; reverse transcription Molecular diagnostics; mutation scanning, by physical properties (eg, single strand conformational polymorphisms [SSCP], heteroduplex, denaturing gradient gel electrophoresis [DGGE], RNA'ase A), single segment, each Molecular diagnostics; mutation identification by sequencing, single segment, each segment Molecular diagnostics; mutation identification by allele specific transcription, single segment, each segment Molecular diagnostics; mutation identification by allele specific translation, single segment, each segment Molecular diagnostics; lysis of cells prior to nucleic acid extraction (eg, stool specimens, paraffin embedded tissue), each specimen Molecular diagnostics; amplification, signal, each nucleic acid sequence Molecular diagnostics; separation and identification by high resolution technique (eg, capillary electrophoresis), each nucleic acid preparation Molecular diagnostics; interpretation and report Molecular cytogenetics; DNA probe, each (eg, FISH) Molecular cytogenetics; chromosomal in situ hybridization, analyze 3-5 cells (eg, for derivatives and markers) HCPC S3818 S3819 S3820 S3822 Complete gene sequence analysis; BRCA 1 gene Complete gene sequence analysis; BRCA 2 gene Complete BRCA1 and BRCA2 gene sequence analysis for susceptibility to breast and ovarian cancer Single mutation analysis (in individual with a known 05/12/2010 sbm preliminary approved by Dr. Stemple 05/26/2010 sbm List approved by Kira Prewitt-Eddy, MPA 12/09/2010 sbm 2010/2011 review completed, no changes 02/06/2012 sbm Addition of , 2012 CPT updates 02/07/2012 sbm Code list approved by Tammy Mullins, R.N. and Kira Prewitt-Eddy 13

16 BRCA1 and BRCA2 Testing BRCA1 or BRCA2 mutation in the family) for susceptibility to breast and ovarian cancer S3823 ICD-10-CM Diagnosis Z8Ø.3 Three-mutation BRCA1 and BRCA2 analysis for susceptibility to breast and ovarian cancer in Ashkenazi individuals Family history of malignant neoplasm of Breast Z12.39 Encounter for otherscreening for malignant neoplasm of breast Z13.71 Encounter for nonprocreative screening for genetic disease carrier status Z13.79 Encounter for other screening for genetic and chromosomal anomalies Z13.89 Encounter for screening for other disorder HCPC S3818 S3819 S3820 S3822 S3823 ICD-10-CM Diagnosis Z8Ø.3 Complete gene sequence analysis; BRCA 1 gene Complete gene sequence analysis; BRCA 2 gene Complete BRCA1 and BRCA2 gene sequence analysis for susceptibility to breast and ovarian cancer Single mutation analysis (in individual with a known BRCA1 or BRCA2 mutation in the family) for susceptibility to breast and ovarian cancer Three-mutation BRCA1 and BRCA2 analysis for susceptibility to breast and ovarian cancer in Ashkenazi individuals Family history of malignant neoplasm of Breast Z12.39 Encounter for otherscreening for malignant neoplasm of breast Z13.71 Encounter for nonprocreative screening for genetic disease carrier status 05/12/2010 sbm preliminary approved by Dr. Stemple 05/26/2010 sbm List approved by Kira Prewitt-Eddy, MPA 12/09/2010 sbm 2010/2011 review completed, no changes 02/06/2012 sbm Addition of , 2012 CPT updates 02/07/2012 sbm Code list approved by Tammy Mullins, R.N. and Kira Prewitt-Eddy 14

17 BRCA1 and BRCA2 Testing Z13.79 Encounter for other screening for genetic and chromosomal anomalies Z13.89 Encounter for screening for other disorder 05/12/2010 sbm preliminary approved by Dr. Stemple 05/26/2010 sbm List approved by Kira Prewitt-Eddy, MPA 12/09/2010 sbm 2010/2011 review completed, no changes 02/06/2012 sbm Addition of , 2012 CPT updates 02/07/2012 sbm Code list approved by Tammy Mullins, R.N. and Kira Prewitt-Eddy 15

18 Breast Cancer, Screening Provider Claims CPT Screening mammography, bilateral (2-view film study of each breast) HCPCS G0202 ICD-10-CM Diagnosis Screening mammography, producing direct digital image, bilateral, all views Z12.31 Encounter for screening mammogram for malignant neoplasm of breast 05/12/2010 sbm approved by Dr. Stemple Removed preventive codes, added G /18/2010 sbm CERT approved, delete /09/2010 sbm 2010/2011 review completed, no changes 02/06/2012 sbm 2012 review completed, no changes 16

19 Breastfeeding Support, Supplies, and Counseling Provider Claims CPT Home visit for postnatal assessment and follow-up care A home visit for postnatal assessment may include a review of plans for future health maintenance and care, including routine infant immunizations, identification of illness and periodic health evaluations, and linking the family with other sources of support such as social services, parenting classes, and lactation consultants as necessary. HCPC A4281 A4282 A4283 A4284 A4285 A4286 E0602 E0603 E0604 S9443 ICD-10-CM Diagnosis Tubing for breast pump, replacement Adapter for breast pump, replacement Cap for breast pump bottle, replacement Breast shield and splash protector for use with breast pump, replacement Polycarbonate bottle for use with breast pump, replacement Locking ring for breast pump, replacement Breast pump, manual, any type Breast pump, electric (AC and/or DC), any type Breast pump, hospital grade, electric (AC and/or DC), any type Lactation classes, nonphysician provider, per session Z39.1 Encounter for care and examination of lactating mother 10/05/2011 sbm Completed 17

20 Cervical Cancer Screening Provider Claims CPT Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician (Use in conjunction with , , ) Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision Cytopathology, slides, cervical or vaginal; manual screening under physician supervision Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening using cell selection and review under physician supervision Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and rescreening under physician supervision 05/18/2010sbm Completed 05/18/2010 sbm CERT approved with deletion of 88155, V15.89, V73.81, V76.47, V /27/2010 sbm Approved by CERT members for Peds 12/09/2010 sbm Addition of V72.31, V /03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 02/06/2012 sbm Addition of S0610-S

21 Cervical Cancer Screening Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening under physician supervision Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening using cell selection and review under physician supervision Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with rescreening by automated system and manual rescreening or review, under physician supervision HCPC G0123 G0124 G0141 G0143 G0144 G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician Screening cytopathology smears, cervical or vaginal performed by automated system, with manual rescreening, requiring interpretation by physician Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision 05/18/2010sbm Completed 05/18/2010 sbm CERT approved with deletion of 88155, V15.89, V73.81, V76.47, V /27/2010 sbm Approved by CERT members for Peds 12/09/2010 sbm Addition of V72.31, V /03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 02/06/2012 sbm Addition of S0610-S

22 Cervical Cancer Screening G0147 G0148 P3000 P3001 Q0091 S0610 S0612 S0613 ICD-10-CM Diagnosis ZØ1.411 ZØ1.419 Screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening Screening Papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision Screening Papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory Annual gynecological examination, new patient Annual gynecological examination, established patient Annual gynecological examination; clinical breast examination without pelvic evaluation Encounter for gynecological examination (general) (routine) with abnormal findings Encounter for gynecological examination (general) (routine) without abnormal findings Z12.4 Encounter for screening for malignant neoplasm of cervix 05/18/2010sbm Completed 05/18/2010 sbm CERT approved with deletion of 88155, V15.89, V73.81, V76.47, V /27/2010 sbm Approved by CERT members for Peds 12/09/2010 sbm Addition of V72.31, V /03/2011 sbm Per Drs. Knispel and Masten, V72.32 should not be included as they are diagnostic in nature. 02/06/2012 sbm Addition of S0610-S

23 Chlamydia Screen Provider Claims CPT Culture, chlamydia, any source Infectious agent antigen detection by immunofluorescent technique; Chlamydia trachomatis Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple-step method; Chlamydia trachomatis Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique Infectious agent antigen detection by immunoassay with direct optical observation; chlamydia trachomatis ICD-10-CM Diagnosis Z11.8 Encounter for screening for other infections and parasitic diseases 05/12/2010 sbm Removed 86632, 87110, 87270, 87320, 87490, 87491, 87492, per Dr. Stemple 05/18/2010 sbm CERT approved with deletion of V73.81, V73.89, V73.99, /09/2010 sbm 2010/2011 review completed, no changes 02/07/2012 sbm Addition of G /21/2012 sbm Deletion of G

24 Colorectal Cancer Screening Provider Claims CPT Sigmoidoscopy, flexible; diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure) Sigmoidoscopy, flexible; with biopsy, single or multiple Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery Sigmoidoscopy, flexible; with directed submucosal injection(s), any substance Sigmoidoscopy, flexible; with removal tumor(s), polyp(s), or other lesion(s) by snare technique Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique Colonoscopy, flexible, proximal to splenic flexure; diagnostic, with or without collection of specimen(s) by brushing or washing, with or without colon decompression (separate procedure) Colonoscopy, flexible, proximal to splenic flexure; with biopsy, single or multiple Colonoscopy, flexible, proximal to splenic flexure; with directed submucosal injection(s), any substance Colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique Completed sbm 01/25/2008 sbm Removed deleted code G /3/08 tdb- Added G0328, S3830, 45335, /01/2009 sbm 2009 review completed, no changes 04/13/2010 sbm Added V16.0 per 2007 decision made in Corporate Claims Counsel 05/07/2010 sbm Added V18.51 to preventive/routine (05/12/ Dr. Stemple agreed this should be included) 05/12/2010 sbm Per Dr. Stemple, codes for virtual colonoscopy should be included due to state mandates. 05/18/2010 sbm CERT review, delete S3890, V /20/2010 sbm Removed from HCR list, per Drs. Stemple and Roberts 12/09/2010 sbm Addition of 74261, 74262, 74263, no other changes 10/03/2011 sbm Deletion of 74261, 74262, per Dr. Stemple. These codes will pend for review. 02/07/2012 sbm 2012 review completed, no changes 22

25 Colorectal Cancer Screening Radiologic examination, colon; barium enema, with or without KUB Radiologic examination, colon; air contrast with specific high density barium, with or without glucagon Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided three cards or single triple card for consecutive collection) Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations HCPC G0104 G0105 Colorectal cancer screening; flexible sigmoidoscopy Colorectal cancer screening; colonoscopy on individual at high risk G0106 Colorectal cancer screening; alternative to G0104, screening sigmoidoscopy, barium enema G0120 Colorectal cancer screening; alternative to G0105, screening colonoscopy, barium enema G0121 G0122 G0328 ICD-10-CM Diagnosis Z8Ø.Ø Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk Colorectal cancer screening; barium enema Colorectal cancer screening; fecal-occult blood test, immunoassay, 1-3 simultaneous determinations Family history of malignant neoplasm of digestive organs Z83.71 Family history of Colonic polyps Completed sbm 01/25/2008 sbm Removed deleted code G /3/08 tdb- Added G0328, S3830, 45335, /01/2009 sbm 2009 review completed, no changes 04/13/2010 sbm Added V16.0 per 2007 decision made in Corporate Claims Counsel 05/07/2010 sbm Added V18.51 to preventive/routine (05/12/ Dr. Stemple agreed this should be included) 05/12/2010 sbm Per Dr. Stemple, codes for virtual colonoscopy should be included due to state mandates. 05/18/2010 sbm CERT review, delete S3890, V /20/2010 sbm Removed from HCR list, per Drs. Stemple and Roberts 12/09/2010 sbm Addition of 74261, 74262, 74263, no other changes 10/03/2011 sbm Deletion of 74261, 74262, per Dr. Stemple. These codes will pend for review. 02/07/2012 sbm 2012 review completed, no changes 23

26 Colorectal Cancer Screening Z12.12 Encounter for screening for malignant neoplasms of Rectum Z12.11 Encounter for screening for malignant neoplasms of Colon Completed sbm 01/25/2008 sbm Removed deleted code G /3/08 tdb- Added G0328, S3830, 45335, /01/2009 sbm 2009 review completed, no changes 04/13/2010 sbm Added V16.0 per 2007 decision made in Corporate Claims Counsel 05/07/2010 sbm Added V18.51 to preventive/routine (05/12/ Dr. Stemple agreed this should be included) 05/12/2010 sbm Per Dr. Stemple, codes for virtual colonoscopy should be included due to state mandates. 05/18/2010 sbm CERT review, delete S3890, V /20/2010 sbm Removed from HCR list, per Drs. Stemple and Roberts 12/09/2010 sbm Addition of 74261, 74262, 74263, no other changes 10/03/2011 sbm Deletion of 74261, 74262, per Dr. Stemple. These codes will pend for review. 02/07/2012 sbm 2012 review completed, no changes 24

27 Condoms (Male/Female), Spermicide (Foam/Sponge) Provider Claims HCPC A4267 A4268 A4269 ICD-10-CM Diagnosis Z3Ø.Ø18 Z3Ø.Ø2 Z3Ø.Ø9 Z3Ø.4Ø Hospital Revenue Contraceptive supply, condom, male, each Contraceptive supply, condom, female, each Contraceptive supply, spermicide (e.g., foam, gel), each Encounter for initial prescription of other contraceptives Counseling and instruction in natural family planning to avoid pregnancy Encounter for other general counseling and advice on contraception Encounter for surveillance of contraceptives, unspecified 0272 Medical/Surgical Supplies and Devices Sterile Supply 09/28/2011 sbm Completed 02/16/2012 sbm 2012 review completed 25

28 Contraceptive Injections Provider Claims CPT Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular HCPC J1051 J1055 J1056 ICD-10-CM Z3Ø.Ø18 Z3Ø.Ø2 Z3Ø.Ø9 Z3Ø.4Ø Z3Ø.49 Z3Ø.9 Hospital Revenue Injection, medroxyprogesterone acetate, 50 mg (Depo- Provera) Injection, medroxyprogesterone acetate for contraceptive use, 150 mg (Depo-Provera) Injection, medroxyprogesterone acetate/estradiol cypionate, 5 mg/25 mg (Lunelle) Encounter for initial prescription of other contraceptives Counseling and instruction in natural family planning to avoid pregnancy Encounter for other general counseling and advice on contraception Encounter for surveillance of contraceptives, unspecified Encounter for surveillance of other contraceptives Encounter for contraceptive management; unspecified 0260 IV Therapy General 0361 Operating Room Services Minor Surgery 0450 Emergency Room General 0510 Clinic General Classification 0511 Clinic Chronic Pain Center 0514 Clinic OB/GYN Clinic Completed sbm 02/20/2009 sbm 2009 updates completed 05/05/2010 sbm 2010 review completed 04/28/2011 sjk 2011 review completed 02/16/2012 sbm 2012 review completed 26

29 Contraceptive Injections 0515 Clinic Pediatric Clinic 0516 Clinic Urgent Care 0517 Clinic Family Practice Clinic 0519 Clinic Other Clinic 0520 Freestanding Clinic General 0523 Freestanding Clinic Family Practice Clinic 0526 Freestanding Clinic Urgent Care Clinic 0529 Freestanding Clinic Other Freestanding Clinic 0636 Pharmacy Drugs Requiring Detailed Coding 0940 Other Therapeutic Services - General Completed sbm 02/20/2009 sbm 2009 updates completed 05/05/2010 sbm 2010 review completed 04/28/2011 sjk 2011 review completed 02/16/2012 sbm 2012 review completed 27

30 Dental Care Preventive Provider Claims CDT D0120 D0140 D0150 D0210 D0220 D0230 D0270 D0272 D0274 D0330 D0460 D1110 D1120 D1206 D1208 D1351 D1510 D1515 D1550 Periodic Oral Evaluation - Establiished Patient Limited Oral Evaluation - Problem Focused Comprehensive Oral Evaluation - New or Established Patient Intraoral Complete Series of Radiographic Images Intraoral Periapical First Radiographic Image Intraoral Periapical Each Additional Radiographic Image Bitewing Single Radiographic Image Bitewings Two Radiographic Images Bitewings Four Radiographic Images Panoramic Radiographic Image Pulp Vitality Tests Prophylaxis Adult Prophylaxis Child Topical Application of Fluoride Varnish Topical Application of Flouride Excluding Varnish Sealant Per Tooth Space Maintainer Fixed Unilateral Space Maintainer Fixed Bilateral Re-cement or RE-bond Space Maintainer CPT Application of topical fluoride varnish by a physician or other qualified health care professional. 28

31 Diabetes Screening Provider Claims CPT Glucose; quantitative, blood (except reagent strip) Glucose; post glucose dose (includes glucose) Glucose; tolerance test (GTT), three specimens (includes glucose) Hemoglobin; glycosylated (A1C) ICD-10-CM Diagnosis Z13.1 Encounter for screening for Diabetes Mellitus 08/22/2008 sbm Completed 01/12/2009 sbm Review completed, no changes 11/05/2009 sbm Code table updated to match CMS guidelines for Diabetes Screening 05/12/2010 sbm per Dr. Stemple, include A1C code 05/20/2010 sbm Approved by DrStemple and Dr. Roberts and Angela Newman, R.N. 12/10/2010 sbm 2010/2011 review completed, no changes 29

32 Diaphragm Provider Claims CPT Diaphragm or cervical cap fitting with instructions HCPC A4261 A4266 A4269 ICD-10-CM Diagnosis Z3Ø.Ø18 Cervical cap for contraceptive use Diaphragm for contraceptive use Contraceptive Supply, Spermicide (E.G., Foam, Gel), Each Encounter for initial prescription of other contraceptives Z3Ø.Ø2 Z3Ø.Ø9 ICD-10-PCS Procedure ØUHC7HZ ØUHC8HZ ØU2DXHZ ØUPD7HZ ØUPD8HZ Hospital Revenue Counseling and instruction in natural family planning to avoid pregnancy Encounter for other general counseling and advice on contraception Insertion of contraceptive device into cervix, via natural or artificial opening Insertion of contraceptive device into cervix, via natural or artificial opening, Endoscopic Change contraceptive in uterurs and cervix, External approach Removal of contraceptive device from uterus and cervix, via natural or artificial opening Removal of contraceptive device from uterus and cervix, via natural or artificial opening, Endoscopic 0272 Medical/Surgical Supplies and Devices Sterile Supply 0360 Operating Room Services General 09/28/2011 sbm Completed 02/16/2012 sbm 2012 review completed 30

33 Diaphragm 0361 Operating Room Services Minor Surgery 0450 Emergency Room General 0490 Ambulatory Surgical Care General 0510 Clinic General classification 0514 Clinic OB/GYN Clinic 0515 Clinic Urgent Care Clinic 0517 Clinic Family Practice Clinic 0519 Clinic Other Clinic 09/28/2011 sbm Completed 02/16/2012 sbm 2012 review completed 31

34 Gonorrhea Screening Provider Claims CPT Culture, presumptive, pathogenic organisms, screening only Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi, or cell types ICD-10-CM Diagnosis Z11.3 Encounter for screening for infections with a predominantly sexual mode of transmission 11/05/2009 sbm Completed 05/12/2010 sbm Per Dr. Stemple, removed 87590, 87591, /20/2010 sbm Approved by Dr. Stemple, Dr. Roberts, Angela Newman, R.N. 12/10/2010 sbm 2010/2011 review completed, no changes 02/07/2012 sbm Addition of G /21/2012 sbm Deletion of G

35 Hearing Screening Provider Claims CPT Screening test, pure tone, air only Pure tone audiometry (threshold); air only Pure tone audiometry (threshold); air and bone Tympanometry (impedance testing) Select picture audiometry HCPCS V5008 Hearing screening ICD-10-CM ZØØ.129 ZØØ.11Ø ZØØ.111 ZØ1.1Ø ZØ1.118 Encounter for routine child examination without abnormal findings Health examinationfr newborn under 8 days old Health examination for newborn 8 to 28 days old Encounter for examination of ears and hearing without other abnormal findings Encounter for examination of ears and hearing with other abnormal findings 3/11/2010 tdc - completed 04/06/2010 sbm per discussion with Technology Assessment, audio evoked potential testing is now included 05/12/2010 sbm per Dr. Stemple, removed V /20/2010 sbm Removed per Dr. Stemple, Dr. Roberts, Angela Newman, R.N., Jill Lentz, R.N. 07/27/2010 sbm Approved by CERT members for Peds 12/10/2010 sbm Addition of V20.31, V /03/2011 sbm Addition of per American Academy of Pediatrics 02/07/2012 sbm 2012 review completed, no changes 33

36 Hepatitis B Screening Provider Claims CPT Hepatitis B core antibody (HBcAb); total Hepatitis B core antibody (HBcAb); IgM antibody Hepatitis B surface antibody (HBsAb) Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg) Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg) neutralization Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, direct probe technique Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, amplified probe technique ICD-10-CM Diagnosis OØ9.ØØ- OØ9.13 OØ OØ9.299 OØ9.3Ø- OØ9.33 OØ9.4Ø- OØ9.43 OØ OØ9.529 OØ OØ9.629 OØ9.7Ø- OØ9.73 Supervision of high risk pregnancy Supervision of pregnancy with other poor reproductive or obstetric history Supervision of pregnancy with insufficient antenatal care Supervision of pregnancy with grand multiparity Supervision of elderly primigravida and multigravida Supervision of young primigravida and multigravida Supervision of high risk pregnancy due to social problems 05/07/2010 sbm Completed 05/13/2010 sbm Approved by Dr. Stemple 05/20/2010 sbm Approved by Dr. Stemple, Dr. Roberts and Angela Newman, R.N. 12/10/2010 sbm 2010/2011 review completed, no changes 02/07/2012 sbm Addition of G /21/2012 sbm Deletion of G